SCHEMBL4770958

SCHEMBL4770958

CCCCNC(=O)c1ccc(NS(=O)(=O)CCc2ccccc2Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.50
HPGD P15428 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.48
NAMPT P43490 1/20 0.47
KMT2A Q03164 1/20 0.47
TRPV1 Q8NER1 1/20 0.46
NAAA Q02083 1/20 0.45
PTGES2 Q9H7Z7 1/20 0.44
EPHX2 P34913 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
DRD3 P35462 1/20 0.43
CA2 P00918 1/20 0.43
RXFP1 Q9HBX9 1/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 2/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4777693 0.93 HIF1A (0.54) HIF1AL3MBTL1HPGDSMN1; SMN2NAMPT
SCHEMBL4776613 0.89 HIF1A (0.50) HIF1AL3MBTL1HPGDSMN1; SMN2NAMPT
SCHEMBL4772410 0.88 HIF1A (0.55) HIF1AL3MBTL1HPGDSMN1; SMN2NAMPT
SCHEMBL4768066 0.84 PTGES2 (0.49) HIF1AL3MBTL1HPGDSMN1; SMN2NAMPT
SCHEMBL4768057 0.82 L3MBTL1 (0.43) HIF1AL3MBTL1SMN1; SMN2NAMPTKMT2A
SCHEMBL4773557 0.82 L3MBTL1 (0.43) HIF1AL3MBTL1SMN1; SMN2NAMPTKMT2A
SCHEMBL4777421 0.82 L3MBTL1 (0.43) HIF1AL3MBTL1NAMPTKMT2AEPHX2
SCHEMBL4773260 0.82 L3MBTL1 (0.44) HIF1AL3MBTL1NAMPTKMT2ATRPV1
SCHEMBL4767750 0.81 HDAC6 (0.44) HIF1AL3MBTL1NAMPTKMT2AEPHX2
SCHEMBL4777284 0.81 ACLY (0.49) HIF1AL3MBTL1HPGDSMN1; SMN2NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 HIF1A 4386/4885L3MBTL1 2781/4885HPGD 2681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.